Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

LABORATOIRES KOL : revenue, balance sheet and financial ratios

LABORATOIRES KOL is a French company founded 6 years ago, specialized in the sector Fabrication de préparations pharmaceutiques. Based in CLERMONT-FERRAND (63000), this company of category PME shows in 2023 a net income positive of 1.9 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-09

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - LABORATOIRES KOL (SIREN 882021199)
Indicator 2023 2021
Revenue N/C N/C
Net income 1 913 900 € -266 063 €
EBITDA N/C N/C
Net margin N/C N/C

Revenue and income statement

In 2023, LABORATOIRES KOL generates positive net income of 1.9 M€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2023) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

1 913 900 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 38%. Debt remains under control: the company retains capacity to raise new debt if needed. Financial autonomy (= Equity / Total assets x 100) reaches 24%. The balance between equity and debt is satisfactory.

Debt ratio (2023) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

37.718%

Financial autonomy (2023) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

23.802%

Asset age ratio (2023) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

51.4%

Solvency indicators evolution
LABORATOIRES KOL

Sector positioning

Debt ratio
37.72 2023
2021
2023
Q1: 0.0
Med: 2.28
Q3: 51.98
Average +43 pts over 2 years

In 2023, the debt ratio of LABORATOIRES KOL (37.72) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.

Financial autonomy
23.8% 2023
2021
2023
Q1: 25.54%
Med: 52.2%
Q3: 68.87%
Watch +6 pts over 2 years

In 2023, the financial autonomy of LABORATOIRES KOL (23.8%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 135.79. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2023) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

135.794

Liquidity indicators evolution
LABORATOIRES KOL

Sector positioning

Liquidity ratio
135.79 2023
2021
2023
Q1: 112.83
Med: 200.61
Q3: 363.19
Average +16 pts over 2 years

In 2023, the liquidity ratio of LABORATOIRES KOL (135.79) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.

Positioning of LABORATOIRES KOL in its sector

Comparison with sector Fabrication de préparations pharmaceutiques

Valuation estimate

Indicative estimate only : the number of comparable transactions in this sector is limited (27 transactions). This range of 381 859€ to 1 173 688€ is provided for information purposes only and requires in-depth analysis to be confirmed.

Estimated enterprise value 2023
Indicative
381k€ 862k€ 1173k€
862 128 € Range: 381 859€ - 1 173 688€
NAF 5 all-time
How is this estimate calculated?

This estimate is based on the analysis of 27 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Fabrication de préparations pharmaceutiques)

Compare LABORATOIRES KOL with other companies in the same sector:

Voir toutes les statistiques du secteur Fabrication de préparations pharmaceutiques

Frequently asked questions about LABORATOIRES KOL

What is the revenue of LABORATOIRES KOL ?

The revenue of LABORATOIRES KOL is not publicly disclosed (confidential accounts filed with INPI).

Is LABORATOIRES KOL profitable?

Yes, LABORATOIRES KOL generated a net profit of 1.9 M€ in 2023.

Where is the headquarters of LABORATOIRES KOL ?

The headquarters of LABORATOIRES KOL is located in CLERMONT-FERRAND (63000), in the department Puy-de-Dome.

Where to find the tax return of LABORATOIRES KOL ?

The tax return of LABORATOIRES KOL is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does LABORATOIRES KOL operate?

LABORATOIRES KOL operates in the sector Fabrication de préparations pharmaceutiques (NAF code 21.20Z). See the 'Sector positioning' section above to compare the company with its competitors.